Main Management ETF Advisors LLC Purchases Shares of 36,472 Hims & Hers Health, Inc. (NYSE:HIMS)

Main Management ETF Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 36,472 shares of the company's stock, valued at approximately $672,000.

Other hedge funds also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $604,000. Carnegie Investment Counsel acquired a new stake in shares of Hims & Hers Health during the third quarter worth approximately $5,531,000. Royce & Associates LP grew its position in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company's stock worth $6,281,000 after buying an additional 49,500 shares in the last quarter. Versor Investments LP acquired a new stake in shares of Hims & Hers Health during the third quarter worth approximately $634,000. Finally, International Assets Investment Management LLC acquired a new position in Hims & Hers Health in the third quarter worth $6,790,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now owns 184,947 shares in the company, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 45,767 shares of the firm's stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.33, for a total transaction of $747,375.11. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at $1,094,354.95. This represents a 40.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 974,495 shares of company stock valued at $22,548,139 in the last three months. 17.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HIMS. TD Cowen reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a report on Monday, December 2nd. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target for the company. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $21.43.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $2.63 during mid-day trading on Friday, reaching $34.23. The company's stock had a trading volume of 13,460,709 shares, compared to its average volume of 22,864,686. Hims & Hers Health, Inc. has a 12 month low of $8.09 and a 12 month high of $35.02. The business's 50 day simple moving average is $23.54 and its 200 day simple moving average is $20.49. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 77.80 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The business's revenue was up 77.1% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.